RGEN - Repligen Corporation
42.80 0.00 (0.00%)
After hours: 5:24PM EDT
| Previous Close | 42.21 |
| Open | 41.88 |
| Bid | 42.80 x 800 |
| Ask | 44.00 x 900 |
| Day's Range | 41.88 - 42.82 |
| 52 Week Range | 29.56 - 46.81 |
| Volume | 145,367 |
| Avg. Volume | 279,441 |
| Market Cap | 1.87B |
| Beta | 1.13 |
| PE Ratio (TTM) | 59.44 |
| EPS (TTM) | 0.72 |
| Earnings Date | Aug 1, 2018 - Aug 6, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 45.25 |
- Zacks•11 hours ago
Moving Average Crossover Alert: Repligen (RGEN)
Repligen Corporation (RGEN) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front
- GlobeNewswire•12 hours ago
Repligen to Present at Jefferies 2018 Global Healthcare Conference
WALTHAM, Mass., May 23, 2018-- Repligen Corporation, a global bioprocessing company focused on the development and commercialization of highly innovative technologies to improve biopharmaceutical manufacturing ...
- GlobeNewswire•6 days ago
Repligen to Participate in 15th Annual Craig-Hallum Institutional Investor Conference
WALTHAM, Mass., May 17, 2018-- Repligen Corporation, a leading life sciences company focused on bioprocessing technology leadership, today announced that Jon K. Snodgres, Chief Financial Officer, will ...
- Thomson Reuters StreetEvents•13 days ago
Edited Transcript of RGEN earnings conference call or presentation 8-May-18 12:30pm GMT
Q1 2018 Repligen Corp Earnings Call
- Associated Press•15 days ago
Repligen: 1Q Earnings Snapshot
The Waltham, Massachusetts-based company said it had profit of 8 cents per share. Earnings, adjusted for amortization costs and non-recurring costs, were 17 cents per share. The results exceeded Wall Street ...
- GlobeNewswire•15 days ago
Repligen Reports First Quarter 2018 Financial Results
Record quarterly revenue of $44.8 M represents 46% year-over-year growth Revenue guidance raised to $182-$188 million for full year 2018 WALTHAM, Mass., May 08, 2018-- Repligen Corporation, a life sciences ...
- Market Exclusive•22 days ago
Biotechnology Movers: Karyopharm Therapeutics Inc. and Regeneron Pharmaceuticals
So we are now well underway with a fresh week of trading in the biotechnology space and, as we reported yesterday, things have gotten off to a pretty volatile start with a whole host of fresh inputs hitting press at the market open on Monday. Tuesday is no different, with more companies putting out data […] The post Biotechnology Movers: Karyopharm Therapeutics Inc. and Regeneron Pharmaceuticals appeared first on Market Exclusive.
- GlobeNewswire•22 days ago
Analysis: Positioning to Benefit within USA Compression Partners, LP, Kadmon, Repligen, Independent Bank, Leggett & Platt, and Esterline Technologies — Research Highlights Growth, Revenue, and Consolidated Results
NEW YORK, May 01, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of USA ...
- GlobeNewswire•23 days ago
Repligen to Report First Quarter 2018 Financial Results
WALTHAM, Mass., April 30, 2018-- Repligen Corporation today announced that the Company will report its first quarter of 2018 financial results on Tuesday, May 8, 2018. The Company will issue a press release ...
- Motley Fool•27 days ago
3 Top Growth Stocks to Buy Right Now
Repligen, Five Below, and Shopify's growth potential is too good to pass up.
- Motley Fool•29 days ago
3 Top Stocks You Can Buy and Hold for the Next Decade
Ten years is an awfully long time. A.O. Smith, Albemarle, and Repligen will make it worth the wait for patient investors.
Markit•last monthSee what the IHS Markit Score report has to say about Repligen Corp.
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Over the last one-month, outflows of investor capital in ETFs holding RGEN totaled $1.26 billion.
- Motley Fool•last month
My Investing Horror Story: Selling Too Early
Here are three stocks I should have held onto -- but didn't.
Markit•last monthSee what the IHS Markit Score report has to say about Repligen Corp.
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.
- Simply Wall St.•2 months ago
Should You Be Tempted To Sell Repligen Corporation (NASDAQ:RGEN) Because Of Its PE Ratio?
Repligen Corporation (NASDAQ:RGEN) trades with a trailing P/E of 47.6x, which is higher than the industry average of 25.6x. While RGEN might seem like a stock to avoid or sellRead More...
- Simply Wall St.•2 months ago
Repligen Corporation (NASDAQ:RGEN): Is It A Good Long Term Opportunity?
The latest earnings announcement Repligen Corporation’s (NASDAQ:RGEN) released in December 2017 suggested that the business experienced a significant tailwind, more than doubling its earnings from the prior year. Below isRead More...
- GlobeNewswire•2 months ago
Analysis: Positioning to Benefit within Clearwater Paper, Energous, MINDBODY, Agilysys, Repligen, and Unit — Research Highlights Growth, Revenue, and Consolidated Results
NEW YORK, March 20, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
- GlobeNewswire•2 months ago
Repligen Announces Market Launch of OPUS® 80R, Reinforces Technology Leadership in Pre-Packed Chromatography
-First and only available 80 cm diameter pre-packed column to address large-scale clinical and commercial-scale manufacturing of biological drugs-. WALTHAM, Mass., March 20, 2018-- Repligen Corporation, ...
- Simply Wall St.•2 months ago
Will Repligen Corporation’s (NASDAQ:RGEN) Earnings Grow In The Year Ahead?
Since Repligen Corporation (NASDAQ:RGEN) released its earnings in December 2017, analyst consensus outlook seem bearish, as a -50.53% fall in profits is expected in the upcoming year against the pastRead More...
Markit•2 months agoSee what the IHS Markit Score report has to say about Repligen Corp.
Repligen Corp NASDAQ/NGS:RGEN
Markit•3 months agoSee what the IHS Markit Score report has to say about Repligen Corp.
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Over the last one-month, outflows of investor capital in ETFs holding RGEN totaled $155 million.
- Thomson Reuters StreetEvents•3 months ago
Edited Transcript of RGEN earnings conference call or presentation 22-Feb-18 1:30pm GMT
Q4 2017 Repligen Corp Earnings Call
- Associated Press•3 months ago
Repligen beats Street 4Q forecasts
The Waltham, Massachusetts-based company said it had profit of 27 cents per share. Earnings, adjusted for one-time gains and costs, came to 20 cents per share. The results exceeded Wall Street expectations. ...
- ACCESSWIRE•3 months ago
Repligen Corporation to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / February 22, 2018 / Repligen Corporation (NASDAQ: RGEN ) will be discussing their earnings results in their Q4 Earnings Call to be held on February 22, 2018, at 8:30 AM Eastern ...
